Programmable DNA drug platform designed to search and destroy cancer cells upon DNA recognition, targeting previously undruggable mutations.
FinalDose is developing a programmable drug molecule that can be configured with any diseased genetic code to search and destroy cells upon DNA recognition. The company claims the platform can unlock approximately 80% of previously undruggable cancer targets and is starting with all cancers. The site links to a whitepaper describing the complete architecture for cancer therapy. FinalDose is a product of FinalDose.
For people
For agents